[ad_1]
According to two sources close to the Oxford University research, consulted by the Financial Times, the coronavirus vaccine has generated a robust immune response among the elderly, one of the most vulnerable groups.
Furthermore, the British press noted that the antidote increased levels of neutralizing antibodies and T-cells in the elderly, the main purpose of which is to identify and kill invading pathogens.
Despite these positive results, The British newspaper assured that age is still the main risk factor for COVID-19 as the immune system weakens over timeTherefore, this part of the population is the one that will most need protection against the virus.
“If you have data that shows that the vaccine generates good immunity in the 55+ age group and that includes a good response in much older people, I think that’s a promising sign,” said Jonathan Ball, professor of virology. . from the University of Nottingham, in this same medium.
LAST MOMENT: Another UK university announces analysis of Oxford University vaccine data. Friday was Bristol, but today the University of Nottingham ensures that the Oxford vaccine against Covid 19 has generated a robust immune response in the elderly. pic.twitter.com/yhg7HXvObp
– Christian Martin (@askomartin) October 26, 2020
Last July, The Lancet magazine published the results of the early stages of clinical trials, which indicated that the treatment was safe and effective in neutralizing the coronavirus in young people (between 18 and 50 years old).
The vaccine developed by the University of Oxford, which will be available later this year, is currently being tested in the UK, India, South Africa and Brazil, where a clinical trial volunteer died a week ago.
.
[ad_2]
Source link
